glp-1 intestinal paralysis lawsuit in louisiana semaglutide stomach legal team semaglutide gi obstruction law firm in louisiana kentucky semaglutide gastrointestinal obstruction lawyer Kentucky Ozempic Lawyers semaglutide stomach paralysis attorney in semaglutide gastrointestinal obstruction law firm

Product media carousel

Science 326 , 948952

For your appropriate patients with diabetes TOUJEO (insulin glargine) injection 300 Units/mL may provide a different option with a 300 Unit/mL insulin glargine formulation 1 For your appropriate adult patients with diabetes SOLIQUA 100/33 (insulin glargine & lixisenatide) injection 100 Units/mL & 33 mcg/mL offers an alternative option containing Lantus and lixisenatide, a GLP-1 receptor agonist 2 Important Safety Information Important Safety Information for Lantus (insulin glargine injection) 100 Units/mL Contraindications Lantus is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin glargine or any of the excipients in LANTUS

Cross-reactivity is not fully understood

Some animal and early-phase studies noted elevated inflammatory cytokines (IL-6, TNF-) at higher doses, though clinical relevance in humans at therapeutic doses remains unclear

Chemically modified superoxide dismutase (carboxymethylcellulose-SOD and polymethylvinylether-maleic anhydride copolymer-SOD) is effective in the treatment of diabetes and has a therapeutic advantage in clinical use